Kymera Therapeutics (KYMR) Bank of America Global Healthcare Conference 2026 summary

Strategic focus and platform differentiation

• Celebrated 10-year anniversary, reflecting on achievements and future opportunities in targeted protein degradation, with six programs advanced to the clinic and a narrowed focus on immunology.

• Emphasizes unique ability to target difficult proteins with strong biologic rationale and human genetics, aiming to introduce at least one new program annually.

• Current highest priority is executing phase II trials for KT-621 in atopic dermatitis (AD) and asthma, with AD trial completion expected this year and asthma next year; data for both anticipated in 2027.

• Differentiation of STAT6 degraders over inhibitors is based on sustained, complete target degradation, aiming to replicate efficacy of injectable biologics like DUPIXENT.

• Ongoing partnerships with Gilead and Sanofi continue alongside internal programs.

Clinical development and upcoming milestones

• KT-621 phase IIb BROADEN2 study in AD is a dose range finding, placebo-controlled trial with three doses, aiming to select a phase III dose; primary endpoint is percent change in EASI at 16 weeks.

• Asthma phase IIb BREADTH study is ongoing, also with three doses and a 12-week primary endpoint (change in FEV1); both studies will inform phase III dosing for broader indications.

• IRF5 program is in healthy volunteer studies, with data expected in the second half of the year; preclinical data show strong activity in lupus and IBD models.

• Safety profile for KT-621 has been favorable so far, with no major adverse events observed in early studies; conjunctivitis is expected mechanistically but not yet observed.

• Pediatric populations and earlier intervention are strategic priorities, especially given the burden of injections for children.

Market opportunity and competitive landscape

• Large unmet need exists among patients with moderate to severe TH2 diseases not on systemic therapies, with oral options like KT-621 positioned to address aversion to injectables.

• Market entry for KT-621 is expected before DUPIXENT biosimilars, focusing on patients not currently using biologics and aiming for early-line therapy status.

• Both AD and asthma represent significant commercial opportunities, with plans to expand into pediatric and additional type 2 and respiratory indications.

• The company maintains a strong internal discovery engine but is open to in-licensing synergistic immunology assets and strategic partnerships if they expand opportunity breadth.

• Focus remains on small molecule and protein degradation expertise, with potential for combination therapies in the future.